TXNDC2
Thioredoxin domain-containing protein 2
Also known as: SPTRX1, TXND2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86VQ3
- Gene
- TXNDC2
- Ensembl
- ENSG00000168454
- Chromosome
- 18
- Canonical length
- 553 aa
- Protein class
- Predicted intracellular proteins
OverviewNCBI Gene
Enables thioredoxin-disulfide reductase (NADPH) activity. Predicted to be involved in cell redox homeostasis and spermatogenesis. Predicted to act upstream of or within cellular response to reactive oxygen species and flagellated sperm motility. Located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
553 residues, UniProt reviewed canonical sequence.
>Q86VQ3|TXNDC2
1 MDVDKELGME SVKAGASGKP EMRLGTQEET SEGDANESSL LVLSSNVPLL ALEFLEIAQA
61 KEKAFLPMVS HTFHMRTEES DASQEGDDLP KSSANTSHPK QDDSPKSSEE TIQPKEGDIP
121 KAPEETIQSK KEDLPKSSEK AIQPKESNIP KSSAKPIQPK LGNIPKASVK PSQPKEGDIP
181 KAPEETIQSK KEDLPKSSEE AIQPKEGDIP KSSAKPIQPK LGNIAKTSVK PSQPKESDIP
241 KSPEETIQPK EGDIPKSSAK PIQPKLGNIP KASVKPSQPK EGDISKSPEE AIQPKEGDLP
301 KSLEEAIQPK EGDIPKSPEE AIQPKEGDIP KSLEEAIQPK EGDIPKSPEE TIQPKKGDIP
361 KSPEEAIQPK EGDIPKSPKQ AIQPKEGDIP KSLEEAIPPK EIDIPKSPEE TIQPKEDDSP
421 KSLEEATPSK EGDILKPEEE TMEFPEGDKV KVILSKEDFE ASLKEAGERL VAVDFSATWC
481 GPCRTIRPFF HALSVKHEDV VFLEVDADNC EEVVRECAIM CVPTFQFYKK EEKVDELCGA
541 LKEKLEAVIA ELKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TXNDC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.65
- Highest tissue expression
- 98 nTPM
Expression across tissuesHPA
Tissue
- testis: 98 nTPM
- bone marrow: 0.3 nTPM
- adipose tissue: 0.1 nTPM
- adrenal gland: 0.1 nTPM
- amygdala: 0.1 nTPM
- appendix: 0.1 nTPM
Single-cell type
- early spermatids: 393 nCPM
- late spermatids: 154 nCPM
- late primary spermatocytes: 72 nCPM
- neutrophils: 4.1 nCPM
- alveolar cells type 1: 3.8 nCPM
- sertoli cells: 3.1 nCPM
Immune cell
- intermediate monocyte: 0.5 nTPM
- eosinophil: 0.2 nTPM
- myeloid DC: 0.2 nTPM
- classical monocyte: 0.1 nTPM
- basophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- cerebral cortex: 0.5 nTPM
- hypothalamus: 0.5 nTPM
- medulla oblongata: 0.5 nTPM
- pons: 0.5 nTPM
- thalamus: 0.5 nTPM
- cerebellum: 0.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.92
- gnomAD pLI
- 0.63
- gnomAD missense Z
- -0.06
- DepMap mean gene effect
- 0.17
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TXNDC2 as an antibody target. Whether an autoantibody or antibody against TXNDC2 could matter depends on whether native TXNDC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TXNDC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TXNDC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...